Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

238
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
238
Drug Therapy01:28

Drug Therapy

118
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
118
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

2.8K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.8K
Local Anesthetics: Common Agents and Their Applications01:23

Local Anesthetics: Common Agents and Their Applications

623
Local anesthetics (LAs) are commonly used for various applications in medical and dental procedures. Some of the common agents used are cocaine, lidocaine, and bupivacaine.
Cocaine is an ester of benzoic acid and methylecgogine. It is used to anesthetize and vasoconstrict locally. Currently, it is used primarily for topical applications. It is beneficial for surgeries on the upper respiratory tract, providing anesthesia and shrinking the mucosa. Cocaine in the form of cocaine hydrochloride is...
623
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

286
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
286
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

429
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
429

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can Systemic Treatment for Childhood Psoriasis Be Stopped in Cases of Remission? Data From the ACMe Cohort.

Pediatric dermatology·2026
Same author

Treatment-associated phenotype switching between psoriasis and atopic dermatitis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Complete clearance of high-impact sites with risankizumab in patients with psoriasis: a 2-year real-world retrospective multicenter cohort study.

The Journal of dermatological treatment·2026
Same author

Quality of life impairment in vitiligo: A comprehensive review of psychosocial and clinical determinants.

The Journal of international medical research·2026
Same author

Icotrokinra: An Oral Interleukin-23 Receptor Antagonist Peptide for the Treatment of Psoriasis.

American journal of clinical dermatology·2026
Same author

High-Dose, Extended Half-Life IL-23 Inhibitors: the Next Big Step in Psoriasis Care?

Dermatology and therapy·2026

Related Experiment Video

Updated: Oct 15, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K

New Topical Therapies for Psoriasis.

Ana Maria Lé1, Tiago Torres2,3

  • 1Department of Dermatology, Centro Hospitalar Universitário do Porto, Centro Hospitalar do Porto, Edifício das Consultas Externas, Ex. CICAP, Rua D. Manuel II, s/n, 4100, Porto, Portugal.

American Journal of Clinical Dermatology
|October 27, 2021
PubMed
Summary

New topical psoriasis treatments, including tapinarof and roflumilast, show promising efficacy and safety profiles. These advancements offer potential alternatives to traditional therapies for managing chronic skin conditions.

More Related Videos

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

1.2K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

534

Related Experiment Videos

Last Updated: Oct 15, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K
Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

1.2K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

534

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Psoriasis is a chronic, immune-mediated skin disease significantly impacting quality of life.
  • Long-term topical treatments like corticosteroids and vitamin D analogues have limitations due to adverse effects.
  • Emerging therapies aim to address unmet clinical needs in psoriasis management.

Purpose of the Study:

  • To review novel topical agents for psoriasis treatment.
  • To evaluate the efficacy and safety of emerging molecules.
  • To discuss the potential clinical role of new therapies.

Main Methods:

  • Review of Phase III clinical trial data for tapinarof (aryl hydrocarbon receptor modulator).
  • Analysis of Phase III study results for roflumilast (phosphodiesterase type 4 inhibitor).
  • Overview of ongoing preclinical and early clinical investigations targeting pathways like JAK-STAT, IL-2, and RNA modulation.

Main Results:

  • Tapinarof demonstrated efficacy in long-term treatment with a favorable safety profile and a notable remitting effect (average relapse time >3 months).
  • Roflumilast showed significant lesion improvement and pruritus management with no reported side effects; initial evaluation in intertriginous areas was positive.
  • Brepocitinib targeting the JAK-STAT pathway is pending Phase IIb results, indicating ongoing research in targeted therapies.

Conclusions:

  • New topical agents like tapinarof and roflumilast offer promising efficacy and safety for psoriasis.
  • These emerging treatments may provide valuable alternatives to conventional therapies.
  • Further comparative research is needed to define the role of new drugs in psoriasis treatment guidelines.